La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Viemed Healthcare Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Casey Hoyt

Amministratore delegato

US$1.9m

Compenso totale

Percentuale dello stipendio del CEO	24.4%
Mandato del CEO	6yrs
Proprietà del CEO	5.6%
Durata media del management	6yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Jul 08

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Mar 10

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Dec 09

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Jun 04

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

May 18

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

Mar 03

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Feb 16

Viemed Healthcare (TSE:VMD) Seems To Use Debt Rather Sparingly

Feb 03

If You Had Bought Viemed Healthcare (TSE:VMD) Shares Three Years Ago You'd Have Earned 319% Returns

Jan 21

Did Viemed Healthcare, Inc. (TSE:VMD) Insiders Sell Shares?

Jan 08

Should You Rely On Viemed Healthcare's (TSE:VMD) Earnings Growth?

Dec 22

Declining Stock and Solid Fundamentals: Is The Market Wrong About Viemed Healthcare, Inc. (TSE:VMD)?

Nov 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Casey Hoyt rispetto agli utili di Viemed Healthcare?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2023	n/a	n/a	US$9m
Jun 30 2023	n/a	n/a	US$7m
Mar 31 2023	n/a	n/a	US$6m
Dec 31 2022	US$2m	US$470k	US$6m
Sep 30 2022	n/a	n/a	US$8m
Jun 30 2022	n/a	n/a	US$9m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$2m	US$470k	US$9m
Sep 30 2021	n/a	n/a	US$10m
Jun 30 2021	n/a	n/a	US$11m
Mar 31 2021	n/a	n/a	US$29m
Dec 31 2020	US$2m	US$441k	US$32m
Sep 30 2020	n/a	n/a	US$29m
Jun 30 2020	n/a	n/a	US$29m
Mar 31 2020	n/a	n/a	US$11m
Dec 31 2019	US$2m	US$425k	US$9m
Sep 30 2019	n/a	n/a	US$9m
Jun 30 2019	n/a	n/a	US$8m
Mar 31 2019	n/a	n/a	US$9m
Dec 31 2018	US$2m	US$389k	US$10m
Sep 30 2018	n/a	n/a	US$7m
Jun 30 2018	n/a	n/a	US$9m
Mar 31 2018	n/a	n/a	US$8m
Dec 31 2017	US$1m	US$235k	US$8m
Sep 30 2017	n/a	n/a	US$11m
Dec 31 2016	US$231k	US$227k	US$1m

Compensazione vs Mercato: La retribuzione totale di Casey ($USD 1.93M ) è superiore alla media delle aziende di dimensioni simili nel mercato Canadian ($USD 787.08K ).

Compensazione vs guadagni: La retribuzione di Casey è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Casey Hoyt (46 yo)

6yrs

Mandato

US$1,925,507

Compensazione

Mr. Casey Hoyt has been Director of Viemed Healthcare, Inc. since December 14, 2016 and Chief Executive Officer since December 2017. Mr. Hoyt served as Chief Executive Officer of Patient Home Monitoring Co...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Casey Hoyt	CEO & Director	6yrs	US$1.93m	5.59% $ 17.4m
Michael Moore	President	6yrs	US$1.48m	4.72% $ 14.7m
Trae Fitzgerald	Chief Financial Officer	6yrs	US$628.81k	0.15% $ 459.9k
William Zehnder	COO & Director	6yrs	US$1.47m	0.50% $ 1.6m
William Frazier	Chief Medical Officer & Director	6yrs	US$341.94k	0.17% $ 527.2k
Jeremy Trahan	Chief Legal Officer and Executive VP of Acquisitions & Strategic Transactions	1.3yrs	Nessun dato	0.0098% $ 30.7k
Michael Freeman	Chief Business Development Officer	1.3yrs	Nessun dato	Nessun dato
Patrick Eagan	General Counsel & Corporate Secretary	2.5yrs	Nessun dato	0% $ 0

6.0yrs

Durata media

45.5yo

Età media

Gestione esperta: Il team dirigenziale di VMD è esperto e expertise (durata media dell'incarico 6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Casey Hoyt	CEO & Director	7yrs	US$1.93m	5.59% $ 17.4m
William Zehnder	COO & Director	6yrs	US$1.47m	0.50% $ 1.6m
William Frazier	Chief Medical Officer & Director	6yrs	US$341.94k	0.17% $ 527.2k
Randolph Dobbs	Independent Chairman	6yrs	US$213.07k	0.25% $ 770.3k
Nitin Kaushal	Independent Director	6yrs	US$193.22k	0.30% $ 940.6k
Sabrina Heltz	Independent Director	3.1yrs	US$182.22k	0.099% $ 309.6k
Timothy Smokoff	Independent Director	6yrs	US$190.22k	0.21% $ 655.5k
Bruce Greenstein	Independent Director	5.4yrs	US$190.85k	0.17% $ 534.0k

6.0yrs

Durata media

57.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di VMD sono considerati esperti (durata media dell'incarico 6 anni).

Viemed Healthcare Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Independent Director exercised options and sold CA$116k worth of stock

CEO & Director exercised options and sold CA$133k worth of stock

Independent Director exercised options and sold CA$135k worth of stock

CEO & Director exercised options and sold CA$147k worth of stock

Independent Director exercised options and sold CA$206k worth of stock

Recent updates

Viemed Healthcare, Inc. Provides Revenue Guidance for the Third Quarter of 2024

Viemed Healthcare, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2024

Viemed Healthcare, Inc., Annual General Meeting, Jun 06, 2024

Viemed Healthcare, Inc. Provides Earnings Guidance for the First Quarter of 2024

Third quarter 2023 earnings: EPS misses analyst expectations

Is Viemed Healthcare (TSE:VMD) A Risky Investment?

Consensus EPS estimates fall by 11%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viemed Healthcare, Inc. Provides Revenue Guidance for Third Quarter of 2023

Independent Director exercised options and sold CA$116k worth of stock

Consensus EPS estimates increase by 15%

The Returns On Capital At Viemed Healthcare (TSE:VMD) Don't Inspire Confidence

Consensus EPS estimates increase by 57%

CEO & Director exercised options and sold CA$133k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2023

Investor sentiment improves as stock rises 15%

Consensus EPS estimates increase by 15%

Independent Director exercised options and sold CA$135k worth of stock

Investor sentiment improves as stock rises 19%

Consensus EPS estimates fall by 26%

Full year 2022 earnings: EPS misses analyst expectations

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Viemed Healthcare, Inc. Wins Complete Overruling of Appealed Office of Inspector General Claims Resolving Multiyear Process with HHS and CMS

CEO & Director exercised options and sold CA$147k worth of stock

Independent Director exercised options and sold CA$206k worth of stock

Insufficient new directors

Consensus EPS estimates increase by 58%

Viemed Healthcare, Inc. Provides Revenue Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Viemed Healthcare (TSE:VMD) Have A Healthy Balance Sheet?

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Announces Earnings Guidance for the Third Quarter of 2022

Viemed Announces Management Appointments

Some Investors May Be Worried About Viemed Healthcare's (TSE:VMD) Returns On Capital

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Announces Publication of Peer-Reviewed NIVH Study Finding Treatment Reduces Healthcare Costs and Saves Lives

Viemed Healthcare, Inc.(NasdaqCM:VMD) dropped from Russell 2000 Dynamic Index

CEO & Director exercised options and sold CA$103k worth of stock

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Viemed Healthcare, Inc. Provides Revenue Guidance for the Second Quarter of 2022

Insufficient new directors

Viemed Healthcare, Inc., Annual General Meeting, Jun 09, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Viemed Healthcare, Inc. Provides Revenue Guidance for the First Quarter of 2022

Does This Valuation Of Viemed Healthcare, Inc. (TSE:VMD) Imply Investors Are Overpaying?

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Viemed Healthcare (TSE:VMD) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.045 (vs US$0.072 in 3Q 2020)

Independent Chairman exercised options to buy CA$79k worth of stock.

Viemed Healthcare, Inc. Provides Earnings Guidance for the Third Quarter of 2021

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.50 in 2Q 2020)

Shareholders May Not Be So Generous With Viemed Healthcare, Inc.'s (TSE:VMD) CEO Compensation And Here's Why

Viemed Healthcare (TSE:VMD) Could Easily Take On More Debt

CEO & Director exercised options and sold CA$814k worth of stock

Consensus forecasts updated

First quarter 2021 earnings released: EPS US$0.043 (vs US$0.11 in 1Q 2020)

Viemed Healthcare, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Analysts lower EPS estimates to US$0.25

Full year 2020 earnings released: EPS US$0.81 (vs US$0.23 in FY 2019)

Earnings beat expectations, revenue disappoints

Viemed Healthcare, Inc.'s (TSE:VMD) Stock Is Going Strong: Is the Market Following Fundamentals?

I Ran A Stock Scan For Earnings Growth And Viemed Healthcare (TSE:VMD) Passed With Ease

Commonwealth Primary Care ACO and Viemed Healthcare Announce an Innovative Chronic Respiratory Care and Sleep Management Alliance

New 90-day high: CA$12.80